ClinicalTrials.gg
RecruitingNCT04823299AWARE-2Updated Sep 3, 2026

Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation

An interventional study of PVI-ONLY, CONTROL ARM and PVI-PLUS ARM, INTERVENTIONAL ARM in Atrial Fibrillation, Catheter Ablation and Radiofrequency Catheter Ablation, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
556
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation — 7 open to participants now, 11 under way, none of them phase 3. Atrial Fibrillation · Ottawa Heart Institute Research Corporation.

Planned enrollment
2nd of 21
556 · median 102
Started
2026
with 1 other
No phase
18 of 24
6 open now
Primary completion
2029-03
later than 7 of 10 live
Registered
19th of 24
by date

Among the 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 18 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 19th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Atrial Fibrillation by Ottawa Heart Institute Research Corporation, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is a common heart rhythm disorder affecting over a million people in North America and is associated with serious complications including stroke, heart failure, reduced quality of life, and premature death. Catheter ablation has been shown to be more effective than medications for controlling symptoms and reducing the risk of these complications; however, recurrence of AF after ablation remains a significant challenge, often due to incomplete or ineffective initial procedures. This clinical trial aims to determine whether a novel, patient-tailored ablation strategy can improve outcomes compared to the current standard-of-care approach. Participants will be randomly assigned to undergo either standard pulmonary vein isolation or a more individualized ablation procedure that identifies and targets patient-specific sources of AF. All participants will undergo the ablation procedure, receive continuous heart rhythm monitoring, and be followed over time to assess recurrence and safety outcomes.

Read the detailed description

This study is a randomized controlled trial evaluating two different catheter ablation strategies for patients with paroxysmal atrial fibrillation (AF). Participants are randomly assigned in a 1:1 ratio to either the control arm or the experimental arm prior to undergoing their ablation procedure. In the control arm, patients receive a pulmonary vein isolation (PVI)-only strategy using pulsed field ablation (PFA). This approach targets only the pulmonary veins, which are the most common source of AF triggers, and does not include additional ablation beyond isolating these veins. In contrast, the experimental arm uses a more comprehensive PVI-PLUS strategy with radiofrequency ablation (RFA). In addition to standard pulmonary vein isolation, this strategy includes patient-specific ablation of non-pulmonary vein triggers and abnormal atrial substrate, such as low-voltage areas identified during electrophysiologic testing. This individualized approach aims to reduce arrhythmia recurrence by addressing additional sources of AF beyond the pulmonary veins.

All participants undergo their assigned catheter ablation procedure as part of routine clinical care, with procedural details tailored according to the randomized strategy. Following the ablation, patients receive an implantable loop recorder (ILR), which is a small device placed under the skin that continuously monitors heart rhythm. The ILR allows for continuous, long-term detection of atrial arrhythmias, including both symptomatic and asymptomatic episodes, ensuring accurate assessment of treatment outcomes throughout the study period.

Participants are followed closely for a total of 24 months after the ablation procedure. During this follow-up period, patients attend scheduled visits at 2, 6, 12, 18, and 24 months, where ILR data are reviewed and clinical assessments are performed. The continuous monitoring provided by the ILR is central to evaluating the study's primary and secondary outcomes, including recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia. In addition to rhythm monitoring, patients complete quality-of-life questionnaires at baseline and at 24 months, and any repeat procedures, hospital visits, or complications are recorded. This structured follow-up ensures comprehensive evaluation of both the effectiveness and safety of the two ablation strategies over time.

03

Conditions studied

  • Atrial Fibrillation
  • Catheter Ablation
  • Radiofrequency Catheter Ablation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years on the date of consent for the trial.
  2. Subjects must have paroxysmal AF with at least one episode of AF over the past 12 months (patients on antiarrhythmic medications do not need to satisfy this criterion).

    At least one episode of AF documented on 12-lead , Holter monitor, Trans-telephonic monitor (TTM) or Loop Recorder.

  3. Subjects must be able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Persistent and permanent AF.
  2. History of previous catheter or surgical ablation for AF, AFl, AT, Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reentrant Tachycardia (AVRT).
  3. Documented AVNRT, AVRT, AT or Atrial Flutter prior to enrolment in the trial.
  4. Previous left atrial (LA) ablation or LA surgery.
  5. Previous pulmonary vein stenosis or pulmonary vein stent.
  6. Pre-existing hemi-diaphragmatic paralysis.
  7. Active intracardiac thrombus.
  8. to systemic oral anticoagulation therapy
  9. Current therapy (, biologic immunomodulators; such patients may be considered if they can safely discontinue immunosuppressants for three months prior to and for three months following catheter ablation).
  10. Reversible causes of AF (e.g., uncontrolled hyperthyroidism, within six months of cardiac surgery).
  11. \<35%.
  12. Class 4 heart failure.
  13. Hypertrophic cardiomyopathy
  14. Significant valve disease (moderate or severe mitral/aortic stenosis or regurgitation).
  15. Patients with mechanical mitral prosthetic valves
  16. Known adverse reaction to adenosine.
  17. Chronic Kidney Disease ≥ Stage 4.
  18. Significant congenital heart disease (including atrial septal defects or pulmonary vein abnormalities; however, subjects with patent foramen ovale will not be excluded).
  19. Pregnant subjects.
  20. Cerebral ischemic event (stroke or ) in the six months prior to consenting for the trial.
  21. History of thromboembolic events in the 6 months preceding enrollment.
  22. Currently participating or anticipated to participate in interventional clinical trials of drug, device or biologic agents that could affect the results of this trial.
  23. Primary pulmonary hypertension
  24. Rheumatic heart disease
  25. Thrombocytosis, thrombocytopenia and other hypercoagulable states
  26. Active systemic infection
  27. Patients with less than 12 months.
  28. Unwilling or unable to comply fully with study procedures and follow-up.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
556 participants (estimated)

Study arms

  • Active comparator
    PVI-ONLY ablation

    Pulsed Field Ablation (PFA), control arm

    Procedure: PVI-ONLY, CONTROL ARM

  • Experimental
    PVI-PLUS ablation

    RADIOFREQUENCY CATHETER ABLATION (RFA), interventional arm

    Procedure: PVI-PLUS ARM, INTERVENTIONAL ARM

Interventions

  • ProcedurePVI-ONLY, CONTROL ARM

    PULSED FIELD ABLATION (PFA) PVI-ONLY STRATEGY: CONTROL ARM

  • ProcedurePVI-PLUS ARM, INTERVENTIONAL ARM

    RADIOFREQUENCY CATHETER ABLATION (RFA) PVI-PLUS : INTERVENTION ARM

06

What researchers measure

Primary outcomes

  1. Freedom from atrial fibrillation, atrial flutter or atrial tachycardia

    AF, AFl or AT, symptomatic or asymptomatic lasting ≥ 30 seconds

    Time frame: 61 to 730 days after ablation

Secondary outcomes

  1. Atrial fibrillation burden

    Total duration of AF recorded on ambulatory monitoring/total duration of monitoring

    Time frame: 730 days

  2. Long-term rate of documented atrial fibrillation, atrial flutter or atrial tachycardia

    Long-term rate of documented AF, AFl or AT lasting ≥ 30 seconds

    Time frame: 730 days

  3. Incidence of any ECG/ILR documented atrial fibrillation, atrial flutter or atrial tachycardia

    Incidence of any ECG/ILR documented AF, AFl or AT (symptomatic or asymptomatic; lasting ≥ 30 seconds

    Time frame: First 60 days after catheter ablation

  4. Ablation procedure duration

    Catheter ablation procedure time

    Time frame: On day of ablation

  5. Fluoroscopic exposure

    Fluoro time in minutes

    Time frame: On day of ablation

  6. Composite Safety outcomes

    Procedure Related Complications at any time including Stroke, PV stenosis, pericarditis, phrenic nerve palsy, cardiac perforation, atrio-esophageal fistula, major bleeding and/or death.

    Time frame: 730 days

  7. Emergency room visits or hospitalization due to recurrent atrial fibrillation, atrial flutter or atrial tachycardia

    Emergency room visits or hospitalization due to recurrent atrial fibrillation, atrial flutter or atrial tachycardia

    Time frame: 730 days

  8. Repeat catheter ablation for atrial fibrillation, atrial flutter or atrial tachycardia

    Repeat catheter ablation for atrial fibrillation, atrial flutter or atrial tachycardia

    Time frame: 730 days

  9. Quality of life scale

    EuroQol 5-Dimension questionnaire (EQ-5D), scale of 0-100, higher is better perceived health.

    Time frame: 12 and 24 months

  10. Health Economic analyses

    Health Economic analyses

    Time frame: 730 days

  11. Cumulative duration of Atrial Fibrillation, Atrial Flutter or Atrial Tachycardia (atrial burden)

    Cumulative duration of AF, AFL or AT (atrial burden) from day 61 after interventions to end of follow-up

    Time frame: Day 61- Day 730

  12. Comparison of primary outcome events between patients undergoing PVI-ONLY and PVI-PLUS

    Comparison of primary outcome events (freedom from atrial fibrillation, atrial flutter or atrial tachycardia) between patients undergoing PVI only (due to lack of additional triggers/substrate) in the PVI-PLUS strategy and those in the PVI-ONLY group.

    Time frame: 730 days

  13. Fluoroscopic exposure

    Total Air Kerma

    Time frame: On day of ablation

  14. Fluoroscopic exposure

    Dose Area Protocol.

    Time frame: On day of ablation

  15. Quality of life scale

    Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT), 0-100 score range, 100 - no impairment, and 0-very poor quality of life.

    Time frame: 12 and 24 months

  16. Quality of life scale

    Canadian Cardiovascular Society Severity of Atrial Fibrillation (CCS-SAF), score range 0-4, higher score being worse symptoms, or greater impairment.

    Time frame: 12 and 24 months

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 30, 2021
StartActual
Mar 23, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2030
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04823299
Collaborators
Canadian Institutes of Health Research (CIHR), Abbott
Responsible party
Sponsor
First posted
Mar 30, 2021
Start date
Mar 23, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
Sep 3, 2026

Study contacts

Girish Nair, MD
Contact
GNair@ottawaheart.ca
613-696-7272
Sonya Jancar
Contact
sjancar@ottawaheart.ca
613-696-7000 ext. 19678
Girish Nair, MD
principal investigator · Ottawa Heart Institute Research Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion